What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
ASH highlights: groundbreaking results from the TEAMM trial
Final results of the AIM study of ibrutinib and venetoclax in mantle cell lymphoma
Developments that are changing the treatment of CLL - current and future drugs
What are the challenges of allogeneic stem cell transplant in myeloma?